CM
ADPT icon

Caption Management’s Adaptive Biotechnologies ADPT Stock Holding History

Caption Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,200
Closed -$122K – 1248
2023
Q2 		$122K Buy
+18,200
New +$135K ﹤0.01% 972

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Caption Management's ADPT Position: Q3 2023 in Review

Caption Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2023, closing a stake of 18,200 shares — an estimated $122K sold.

Caption Management first reported a position in ADPT in Q2 2023 and held it in 1 quarter. The position peaked at $122K in Q2 2023. 190 funds tracked by Wall St. Rank hold ADPT as of Q3 2023.

  • Caption Management reported no remaining Adaptive Biotechnologies position as of Q3 2023 after selling out during the quarter.
  • Caption Management sold 18,200 Adaptive Biotechnologies shares in Q3 2023, an estimated $122K.
  • Caption Management first reported a position in Adaptive Biotechnologies in Q2 2023 and held it in 1 quarter.
  • Caption Management's Adaptive Biotechnologies position peaked at $122K in Q2 2023.
  • 190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2023.

Based on Caption Management's 13F filing for Q3 2023, filed 14 Nov 2023.